Shopping Cart
- Remove All
- Your shopping cart is currently empty
RECTAS-2.0 is a small molecule designed to correct RNA mis-splicing caused by the GLA c.639+919G>A mutation, intended for research in Fabry disease.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | RECTAS-2.0 is a small molecule designed to correct RNA mis-splicing caused by the GLA c.639+919G>A mutation, intended for research in Fabry disease. |
In vitro | RECTAS-2.0 is capable of restoring normal GLA mRNA splicing and α-galactosidase activity in patient-derived B lymphoblastoid cell lines and cardiomyocytes derived from induced pluripotent stem cells. Furthermore, RECTAS-2.0 shows potential applicability in other genetic diseases involving similar exon competition. |
Molecular Weight | 388.805 |
Formula | C18H17ClN4O4 |
Cas No. | 3038234-95-3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.